PRDS News and Press, Pardes Biosciences Inc. From 07/23/23

NEW YORK, NY / ACCESSWIRE / July 23, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Denbury Inc. (NYSE: DEN)'s sale to ...

NEW YORK, NY / ACCESSWIRE / July 21, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Franchise Group, Inc. (NASDAQ:FRG)'s ...

NEW YORK, NY / ACCESSWIRE / July 20, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: American Equity Investment Life Holdi...

NEW YORK, NY / ACCESSWIRE / July 18, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Chinook Therapeutics, Inc. (NASDAQ:KD...

2023-07-17 10:05:21 ET NASDAQ: PRDS said soared +16.9% said in April that it was exploring an acquisition of the company started a review of strategic alternatives For further details see: Pardes Biosciences soars after co to be acquired by MediPacific

CARLSBAD, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (Nasdaq: PRDS) today announced that it has entered into a definitive merger agreement whereby MediPacific, Inc. (Purchaser) will acquire Pardes for a price per share of not less than $2.02 in cash and an additional cash ...

2023-05-17 19:43:06 ET Summary Pardes Biosciences Seeking Strategic Alternatives. Pardes’ Pipeline is depleted. All-Star management team in place. Significant cash available. Pardes Biosciences Seeking Strategic Alternatives Could See Consolidation Par...

2023-05-05 16:33:00 ET Pardes Biosciences press release ( NASDAQ: PRDS ): Q1 GAAP EPS of -$0.30 beats by $0.11 . Pardes’ cash, cash equivalents and short-term investments as of March 31, 2023, were $172.2 million compared to $197.3 million as of December 31...

CARLSBAD, Calif., May 05, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS) today reported financial results for the first quarter ended March 31, 2023. “As previously announced this year, Pardes Biosciences has initiated a process to evaluate strategic alternativ...

2023-05-02 09:58:49 ET Summary Pardes Biosciences is a busted biopharma that is exploring strategic alternatives and trades at a wide 30% discount to its net cash. The company recently received a buyout proposal from its major shareholder/SPAC sponsor. Pardes Biosciences is li...